In our study, the supplementation of hesperetin with metformin significantly reduced the expression of BACE-1 and APP in vivo, suggesting that the combination improved central insulin resistance and potentially reduced the metformin dosage as a mechanism for enhancing metformin’s efficacy in improving diabetes-induced cognitive impairment. Here, APP is linked to Cognitive impairment.